

John D Isaacs

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5316938/publications.pdf>

Version: 2024-02-01

278
papers

18,448
citations

11608

70
h-index

15683

125
g-index

288
all docs

288
docs citations

288
times ranked

21356
citing authors

#	ARTICLE	IF	CITATIONS
1	EULAR points to consider for therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal diseases. <i>Annals of the Rheumatic Diseases</i> , 2023, 82, 65-73.	0.5	24
2	2021 update of the EULAR points to consider on the use of immunomodulatory therapies in COVID-19. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 34-40.	0.5	26
3	EULAR recommendations for the management and vaccination of people with rheumatic and musculoskeletal diseases in the context of SARS-CoV-2: the November 2021 update. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1628-1639.	0.5	89
4	Pre-defined gene co-expression modules in rheumatoid arthritis transition towards molecular health following anti-TNF therapy. <i>Rheumatology</i> , 2022, 61, 4935-4944.	0.9	3
5	Association between social deprivation and disease activity in rheumatoid arthritis: a systematic literature review. <i>RMD Open</i> , 2022, 8, e002058.	1.8	12
6	P186â€fThe association between social deprivation and disease activity in rheumatoid arthritis: a systematic literature review. <i>Rheumatology</i> , 2022, 61, .	0.9	0
7	OA15â€fDrivers of change in four and two component disease activity scores after etanercept treatment, in a multi-centre cohort of patients with established rheumatoid arthritis. <i>Rheumatology</i> , 2022, 61, .	0.9	0
8	P187â€fPre-defined Gene Co-expression Modules in Rheumatoid Arthritis Transition towards Molecular Health following Tumour Necrosis Factor Inhibitor Therapy. <i>Rheumatology</i> , 2022, 61, .	0.9	1
9	RA-MAP, molecular immunological landscapes in early rheumatoid arthritis and healthy vaccine recipients. <i>Scientific Data</i> , 2022, 9, 196.	2.4	4
10	OA16â€fTherapeutic certolizumab pegol drug levels to achieve good EULAR response in patients with rheumatoid arthritis: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate (BRAGGSS) cohort. <i>Rheumatology</i> , 2022, 61, .	0.9	0
11	Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trial. <i>Nature Medicine</i> , 2022, 28, 1256-1268.	15.2	105
12	Interferon-Î±-mediated therapeutic resistance in early rheumatoid arthritis implicates epigenetic reprogramming. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1214-1223.	0.5	18
13	Characterization of Creatine Kinase Levels in Tofacitinib-Treated Patients with Ulcerative Colitis: Results from Clinical Trials. <i>Digestive Diseases and Sciences</i> , 2021, 66, 2732-2743.	1.1	8
14	Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 71-87.	0.5	158
15	Influenza vaccination and interruption of methotrexate in adult patients in the COVID-19 era: an ongoing dilemma. <i>Lancet Rheumatology</i> , The, 2021, 3, e9-e10.	2.2	9
16	Immunogenicity of biologic agents in rheumatology. <i>Nature Reviews Rheumatology</i> , 2021, 17, 81-97.	3.5	43
17	Why remission is not enough: underlying disease mechanisms in RA that prevent cure. <i>Nature Reviews Rheumatology</i> , 2021, 17, 135-144.	3.5	49
18	Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial. <i>Lancet</i> , The, 2021, 397, 305-317.	6.3	145

#	ARTICLE	IF	CITATIONS
19	EULAR points to consider on pathophysiology and use of immunomodulatory therapies in COVID-19. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 698-706.	0.5	37
20	Transcriptome-wide study of TNF-inhibitor therapy in rheumatoid arthritis reveals early signature of successful treatment. <i>Arthritis Research and Therapy</i> , 2021, 23, 80.	1.6	11
21	Targeting synovial fibroblast proliferation in rheumatoid arthritis (TRAFIC): an open-label, dose-finding, phase 1b trial. <i>Lancet Rheumatology</i> , The, 2021, 3, e337-e346.	2.2	24
22	Biomarkers of tolerance in immune-mediated inflammatory diseases: a new era in clinical management?. <i>Lancet Rheumatology</i> , The, 2021, 3, e371-e382.	2.2	1
23	BIOlogical Factors that Limit sustAined Remission in rhEumatoid arthritis (the BIO-FLARE study): protocol for a non-randomised longitudinal cohort study. <i>BMC Rheumatology</i> , 2021, 5, 22.	0.6	4
24	Pim Kinases as Therapeutic Targets in Early Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2021, 73, 1820-1830.	2.9	14
25	Robust optimization of SWATH-MS workflow for human blood serum proteome analysis using a quality by design approach. <i>Clinical Proteomics</i> , 2021, 18, 20.	1.1	2
26	Half-Dose vs Stable-Dose Conventional Synthetic Disease-Modifying Antirheumatic Drugs and Disease Flare in Patients With Rheumatoid Arthritis. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 872.	3.8	0
27	Characterization of disease course and remission in early seropositive rheumatoid arthritis: results from the TACERA longitudinal cohort study. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2021, 13, 1759720X21110439.	1.2	6
28	Differential DNA methylation correlates with response to methotrexate in rheumatoid arthritis. <i>Rheumatology</i> , 2020, 59, 1364-1371.	0.9	43
29	Immunogenicity of Biosimilars for Rheumatic Diseases, Plaque Psoriasis, and Inflammatory Bowel Disease: A Review from Clinical Trials and Regulatory Documents. <i>BioDrugs</i> , 2020, 34, 27-37.	2.2	35
30	Schrödinger's pipeline and the outsourcing of pharmaceutical innovation. <i>Drug Discovery Today</i> , 2020, 25, 480-484.	3.2	4
31	B Cell Synovitis and Clinical Phenotypes in Rheumatoid Arthritis: Relationship to Disease Stages and Drug Exposure. <i>Arthritis and Rheumatology</i> , 2020, 72, 714-725.	2.9	33
32	O11 Lymphocyte DNA methylation mediates genetic risk at RA risk loci that are shared with other immune mediated diseases. <i>Rheumatology</i> , 2020, 59, .	0.9	0
33	Tolerance-inducing medicines in autoimmunity: rheumatology and beyond. <i>Lancet Rheumatology</i> , The, 2020, 2, e565-e575.	2.2	10
34	Latent Class Trajectory Modeling of 2-Component Disease Activity Score in 28 Joints Identifies Multiple Rheumatoid Arthritis Phenotypes of Response to Biologic Disease-Modifying Antirheumatic Drugs. <i>Arthritis and Rheumatology</i> , 2020, 72, 1632-1642.	2.9	9
35	In search of pathobiological endotypes: a systems approach to early rheumatoid arthritis. <i>Expert Review of Clinical Immunology</i> , 2020, 16, 621-630.	1.3	9
36	Smart battles: immunosuppression versus immunomodulation in the inflammatory RMDs. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 991-993.	0.5	17

#	ARTICLE	IF	CITATIONS
37	EULAR provisional recommendations for the management of rheumatic and musculoskeletal diseases in the context of SARS-CoV-2. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 851-858.	0.5	204
38	Lack of association between clinical and ultrasound measures of disease activity in rheumatoid arthritis remission. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2020, 12, 1759720X2091532.	1.2	6
39	Therapeutic blockade of granulocyte macrophage colony-stimulating factor in COVID-19-associated hyperinflammation: challenges and opportunities. <i>Lancet Respiratory Medicine</i> , 2020, 8, 822-830.	5.2	110
40	Targeting the rheumatoid arthritis synovial fibroblast via cyclin dependent kinase inhibition. <i>Medicine (United States)</i> , 2020, 99, e20458.	0.4	16
41	Lymphocyte DNA methylation mediates genetic risk at shared immune-mediated disease loci. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 145, 1438-1451.	1.5	20
42	Pharmacogenetics of TNF inhibitor response in rheumatoid arthritis utilizing the two-component disease activity score. <i>Pharmacogenomics</i> , 2020, 21, 1151-1156.	0.6	3
43	Basic Mechanisms of JAK Inhibition. <i>Mediterranean Journal of Rheumatology</i> , 2020, 31, 100.	0.3	50
44	Arthritis prevention in the pre-clinical phase of RA with abatacept (the APIPPRA study): a multi-centre, randomised, double-blind, parallel-group, placebo-controlled clinical trial protocol. <i>Trials</i> , 2019, 20, 429.	0.7	77
45	Predicting drug-free remission in rheumatoid arthritis: A prospective interventional cohort study. <i>Journal of Autoimmunity</i> , 2019, 105, 102298.	3.0	34
46	IL-6 Mediated Transcriptional Programming of Naïve CD4+ T Cells in Early Rheumatoid Arthritis Drives Dysregulated Effector Function. <i>Frontiers in Immunology</i> , 2019, 10, 1535.	2.2	17
47	IL-17 expressing inflammatory macrophages in temporal arteries affected by giant cell arteritis. <i>Rheumatology</i> , 2019, 58, .	0.9	0
48	Symptom-based stratification of patients with primary Sjögren's syndrome: multi-dimensional characterisation of international observational cohorts and reanalyses of randomised clinical trials. <i>Lancet Rheumatology</i> , 2019, 1, e85-e94.	2.2	76
49	Living a normal life: a qualitative study of patients' views of medication withdrawal in rheumatoid arthritis. <i>BMC Rheumatology</i> , 2019, 3, 2.	0.6	13
50	Between a ROC and a hard place: Teaching prevalence plots to understand real world biomarker performance in the clinic. <i>Pharmaceutical Statistics</i> , 2019, 18, 632-635.	0.7	2
51	Potential Pharmacologic Targets for the Prevention of Rheumatoid Arthritis. <i>Clinical Therapeutics</i> , 2019, 41, 1312-1322.	1.1	12
52	Generation and validation of an in vitro model of Langhans-type multinucleated giant cells to investigate giant cell arteritis. <i>Rheumatology</i> , 2019, 58, .	0.9	0
53	Approach to therapy in refractory rheumatoid arthritis. <i>Rheumatology</i> , 2019, 58, .	0.9	1
54	Development of novel therapeutics for inflammatory arthritis. <i>Rheumatology</i> , 2019, 58, .	0.9	0

#	ARTICLE	IF	CITATIONS
55	Efficacy and safety of subcutaneous tocilizumab in rheumatoid arthritis over 1 year: a UK real-world, open-label study. <i>Rheumatology Advances in Practice</i> , 2019, 3, rkz010.	0.3	7
56	Association of response to TNF inhibitors in rheumatoid arthritis with quantitative trait loci for <i>CD40</i> and <i>CD39</i> . <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1055-1061.	0.5	25
57	Design of experiments and the virtual PCR simulator: An online game for pharmaceutical scientists and biotechnologists. <i>Pharmaceutical Statistics</i> , 2019, 18, 402-406.	0.7	8
58	Expression of STAT3-regulated genes in circulating CD4+ T cells discriminates rheumatoid arthritis independently of clinical parameters in early arthritis. <i>Rheumatology</i> , 2019, 58, 1250-1258.	0.9	14
59	Routine musculoskeletal ultrasound findings impact diagnostic decisions maximally in autoantibody-seronegative early arthritis patients. <i>Rheumatology</i> , 2019, 58, 1268-1273.	0.9	13
60	SAT0003...PIM1 REGULATES CD4+ T CELL EFFECTOR FUNCTION IN EARLY RHEUMATOID ARTHRITIS AND HAS POTENTIAL FOR USE AS A NOVEL, MEASURABLE THERAPEUTIC TARGET. , 2019, , .		0
61	FRI0009...MOLECULAR PROFILING OF CIRCULATING B-LYMPHOCYTES REVEALS THE SUPERIOR PERFORMANCE OF METHYLOME OVER TRANSCRIPTOME DATA FOR DISCRIMINATING RHEUMATOID ARTHRITIS PATIENTS IN AN EARLY ARTHRITIS CLINIC: IMPLICATIONS FOR TRANSLATING "BIG DATA" INTO CLINICALLY USEFUL TOOLS. , 2019, , .		0
62	Targeting of tolerogenic dendritic cells to heat-shock proteins in inflammatory arthritis. <i>Journal of Translational Medicine</i> , 2019, 17, 375.	1.8	17
63	Tolerising cellular therapies: what is their promise for autoimmune disease?. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 297-310.	0.5	44
64	Macrophage proliferation distinguishes 2 subgroups of knee osteoarthritis patients. <i>JCI Insight</i> , 2019, 4, .	2.3	77
65	Keratinocyte growth factor impairs human thymic recovery from lymphopenia. <i>JCI Insight</i> , 2019, 4, .	2.3	16
66	The interferon gene signature is increased in patients with early treatment-naïve rheumatoid arthritis and predicts a poorer response to initial therapy. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 141, 445-448.e4.	1.5	41
67	CD4+ and B Lymphocyte Expression Quantitative Traits at Rheumatoid Arthritis Risk Loci in Patients With Untreated Early Arthritis. <i>Arthritis and Rheumatology</i> , 2018, 70, 361-370.	2.9	37
68	The RA-MAP Consortium: a working model for academia-industry collaboration. <i>Nature Reviews Rheumatology</i> , 2018, 14, 53-60.	3.5	15
69	Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn's disease and ulcerative colitis?. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 175-187.	0.5	291
70	Targeting of tolerogenic dendritic cells towards heat-shock proteins: a novel therapeutic strategy for autoimmune diseases?. <i>Immunology</i> , 2018, 153, 51-59.	2.0	18
71	Therapeutic tolerance in autoimmune disease. <i>Seminars in Arthritis and Rheumatism</i> , 2018, 48, 558-562.	1.6	15
72	Genome-wide association study of response to tumour necrosis factor inhibitor therapy in rheumatoid arthritis. <i>Pharmacogenomics Journal</i> , 2018, 18, 657-664.	0.9	41

#	ARTICLE	IF	CITATIONS
73	Genome-wide association study of response to methotrexate in early rheumatoid arthritis patients. <i>Pharmacogenomics Journal</i> , 2018, 18, 528-538.	0.9	42
74	Lessons learnt from a discontinued randomised controlled trial: adalimumab injection compared with placebo for patients receiving physiotherapy treatment for sciatica (Subcutaneous Injection of) <i>Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5</i>		
75	Phenotypic and Transcriptomic Analysis of Peripheral Blood Plasmacytoid and Conventional Dendritic Cells in Early Drug Naïve Rheumatoid Arthritis. <i>Frontiers in Immunology</i> , 2018, 9, 755.	2.2	34
76	Biologic refractory disease in rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1405-1412.	0.5	117
77	Achieving consensus on minimum data items (including core outcome domains) for a longitudinal observational cohort study in rheumatoid arthritis. <i>Rheumatology</i> , 2017, 56, kew416.	0.9	3
78	High frequency of antidrug antibodies and association of random drug levels with efficacy in certolizumab pegol-treated patients with rheumatoid arthritis: results from the BRAGGSS cohort. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 208-213.	0.5	49
79	Autologous tolerogenic dendritic cells for rheumatoid and inflammatory arthritis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 227-234.	0.5	243
80	Letâ€™s not fool ourselves. In RA, the ACR/EULAR remission criteria are not perfect!. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, e12-e12.	0.5	6
81	Clinical trials of biosimilars should become more similar. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 4-6.	0.5	20
82	A Genome-wide Association Study Identifies Risk Alleles in Plasminogen and P4HA2 Associated with Giant Cell Arteritis. <i>American Journal of Human Genetics</i> , 2017, 100, 64-74.	2.6	78
83	Patient and researcher perspectives on facilitating patient and public involvement in rheumatology research. <i>Musculoskeletal Care</i> , 2017, 15, 395-399.	0.6	10
84	Synovial tissue research: a state-of-the-art review. <i>Nature Reviews Rheumatology</i> , 2017, 13, 463-475.	3.5	175
85	Drug breakthrough offers hope to arthritis sufferers: qualitative analysis of medical research in UK newspapers. <i>Health Expectations</i> , 2017, 20, 309-320.	1.1	8
86	02.29â€™...Exploring pim1 as a measurable therapeutic target in early rheumatoid arthritis. , 2017, , .		0
87	Considering biosimilar policy. <i>Considerations in Medicine</i> , 2017, 1, 19-24.	0.0	0
88	The biosimilar approval process: how different is it?. <i>Considerations in Medicine</i> , 2017, 1, 3-6.	0.0	25
89	The novel use of combined IL-1 and IL-6 inhibition in a patient with severe, aggressive, erosive, systemic-onset juvenile idiopathic arthritis. <i>European Journal of Rheumatology</i> , 2017, 4, 68-69.	1.3	7
90	The predictive value of serum S100A9 and response to etanercept is not confirmed in a large UK rheumatoid arthritis cohort. <i>Rheumatology</i> , 2017, 56, kew387.	0.9	10

#	ARTICLE	IF	CITATIONS
91	Minimum Information about T Regulatory Cells: A Step toward Reproducibility and Standardization. <i>Frontiers in Immunology</i> , 2017, 8, 1844.	2.2	43
92	Traceless Cleavage of Protein-Biotin Conjugates under Biologically Compatible Conditions. <i>ChemBioChem</i> , 2017, 18, 1688-1691.	1.3	7
93	Subcutaneous Injection of Adalimumab Trial compared with Control (SCIATiC): a randomised controlled trial of adalimumab injection compared with placebo for patients receiving physiotherapy treatment for sciatica. <i>Health Technology Assessment</i> , 2017, 21, 1-180.	1.3	195
94	Capture Hi-C identifies a novel causal gene, IL20RA, in the pan-autoimmune genetic susceptibility region 6q23. <i>Genome Biology</i> , 2016, 17, 212.	3.8	85
95	Components of treatment delay in rheumatoid arthritis differ according to autoantibody status: validation of a single-centre observation using national audit data. <i>Rheumatology</i> , 2016, 55, 1843-1848.	0.9	23
96	Immune reconstitution 20 years after treatment with alemtuzumab in a rheumatoid arthritis cohort: implications for lymphocyte depleting therapies. <i>Arthritis Research and Therapy</i> , 2016, 18, 302.	1.6	21
97	Use of the dendritic cell marker, B and T lymphocyte attenuator, to identify functionally distinct subsets of human CD1c+ dendritic cells. <i>Lancet, The</i> , 2016, 387, S85.	6.3	7
98	A Method to Exploit the Structure of Genetic Ancestry Space to Enhance Case-Control Studies. <i>American Journal of Human Genetics</i> , 2016, 98, 857-868.	2.6	21
99	Differential Methylation as a Biomarker of Response to Etanercept in Patients With Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2016, 68, 1353-1360.	2.9	59
100	<scp>CMV</scp> seropositivity and T cell senescence predict increased cardiovascular mortality in octogenarians: results from the Newcastle 85+ study. <i>Aging Cell</i> , 2016, 15, 389-392.	3.0	103
101	Teaching examples for the design of experiments: geographical sensitivity and the self-fulfilling prophecy. <i>Pharmaceutical Statistics</i> , 2016, 15, 90-92.	0.7	5
102	Detection of anti-drug antibodies using a bridging ELISA compared with radioimmunoassay in adalimumab-treated rheumatoid arthritis patients with random drug levels. <i>Rheumatology</i> , 2016, 55, 2050-2055.	0.9	14
103	Mechanism of action of methotrexate in rheumatoid arthritis, and the search for biomarkers. <i>Nature Reviews Rheumatology</i> , 2016, 12, 731-742.	3.5	290
104	Pregnancy Outcomes in the Tofacitinib Safety Databases for Rheumatoid Arthritis and Psoriasis. <i>Drug Safety</i> , 2016, 39, 755-762.	1.4	112
105	Previously reported <i>PDE3A</i>-SLCO1C1 genetic variant does not correlate with anti-TNF response in a large UK rheumatoid arthritis cohort. <i>Pharmacogenomics</i> , 2016, 17, 715-720.	0.6	9
106	Bcl-2 in CD4+ T Cell-Mediated Rheumatoid Arthritis Pathogenesis: Comment on the Article by Meguro et al. <i>Arthritis and Rheumatology</i> , 2016, 68, 770-771.	2.9	3
107	Synovial CD4+ T-cell-derived GM-CSF supports the differentiation of an inflammatory dendritic cell population in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 899-907.	0.5	86
108	Cytokines in rheumatoid arthritis - shaping the immunological landscape. <i>Nature Reviews Rheumatology</i> , 2016, 12, 63-68.	3.5	385

#	ARTICLE	IF	CITATIONS
109	IL-6-driven STAT signalling in circulating CD4+ lymphocytes is a marker for early anticitrullinated peptide antibody-negative rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 466-473.	0.5	65
110	Biosimilars in immune-mediated inflammatory diseases: initial lessons from the first approved biosimilar anti-tumour necrosis factor monoclonal antibody. <i>Journal of Internal Medicine</i> , 2016, 279, 41-59.	2.7	56
111	Tolerogenic dendritic cells generated with dexamethasone and vitamin D3 regulate rheumatoid arthritis CD4+ T cells partly via transforming growth factor- β 1. <i>Clinical and Experimental Immunology</i> , 2016, 187, 113-123.	1.1	60
112	Minimum information about tolerogenic antigen-presenting cells (MITAP): a first step towards reproducibility and standardisation of cellular therapies. <i>PeerJ</i> , 2016, 4, e2300.	0.9	55
113	Rheumatoid arthritis response to treatment across IgG1 allotype anti-TNF incompatibility: a case-only study. <i>Arthritis Research and Therapy</i> , 2015, 17, 63.	1.6	9
114	Investigating CD11c expression as a potential genomic biomarker of response to TNF inhibitor biologics in whole blood rheumatoid arthritis samples. <i>Arthritis Research and Therapy</i> , 2015, 17, 359.	1.6	6
115	O54. The Importance of IL-6-STAT3 Mediated Activation of Circulating CD4+ T Cells in the Pathogenesis of Early Seronegative Rheumatoid Arthritis: A Validation Study. <i>Rheumatology</i> , 2015, , .	0.9	0
116	Defective removal of ribonucleotides from DNA promotes systemic autoimmunity. <i>Journal of Clinical Investigation</i> , 2015, 125, 413-424.	3.9	190
117	RITPBC: B-cell depleting therapy (rituximab) as a treatment for fatigue in primary biliary cirrhosis: study protocol for a randomised controlled trial: Figure 1. <i>BMJ Open</i> , 2015, 5, e007985.	0.8	19
118	Lost in space: design of experiments and scientific exploration in a Hogarth Universe. <i>Drug Discovery Today</i> , 2015, 20, 1365-1371.	3.2	20
119	Evaluation of the effect of tofacitinib on measured glomerular filtration rate in patients with active rheumatoid arthritis: results from a randomised controlled trial. <i>Arthritis Research and Therapy</i> , 2015, 17, 95.	1.6	46
120	Genotyping in rheumatoid arthritis: a game changer in clinical management?. <i>Expert Review of Clinical Immunology</i> , 2015, 11, 303-305.	1.3	7
121	Progression-seeking bias and rational optimism in research and development. <i>Nature Reviews Drug Discovery</i> , 2015, 14, 219-221.	21.5	12
122	Impact of inadequate adherence on response to subcutaneously administered anti-tumour necrosis factor drugs: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort. <i>Rheumatology</i> , 2015, 54, 494-499.	0.9	90
123	Retrospective analysis of the role of serum vitamin D in early rheumatic disease. <i>Rheumatology</i> , 2015, 54, 374-375.	0.9	4
124	Association of HLA-DRB1 Haplotypes With Rheumatoid Arthritis Severity, Mortality, and Treatment Response. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 1645.	3.8	119
125	O49. Personalized Genetic Medicine: Amino Acid Positions 11, 71 and 74 in HLA-DRB1 Predict Disease Severity, Mortality and Treatment Response in Rheumatoid Arthritis Multi-Centre Prospective Cohort Studies. <i>Rheumatology</i> , 2015, , .	0.9	0
126	Clinical utility of random anti-tumour necrosis factor drug testing and measurement of anti-drug antibodies on long-term treatment response in rheumatoid arthritis. <i>Lancet, The</i> , 2015, 385, S48.	6.3	18

#	ARTICLE	IF	CITATIONS
127	10 years of therapeutic advances in the rheumatic diseases. <i>Nature Reviews Rheumatology</i> , 2015, 11, 628-630.	3.5	4
128	Clinical Utility of Random Anti-Tumor Necrosis Factor Drug Level Testing and Measurement of Antidrug Antibodies on the Long-Term Treatment Response in Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2015, 67, 2011-2019.	2.9	90
129	Why is it hard to terminate failing projects in pharmaceutical R&D?. <i>Nature Reviews Drug Discovery</i> , 2015, 14, 663-664.	21.5	46
130	R&D productivity rides again?. <i>Pharmaceutical Statistics</i> , 2015, 14, 1-3.	0.7	20
131	A Transcriptional Signature of Fatigue Derived from Patients with Primary Sjögren's Syndrome. <i>PLoS ONE</i> , 2015, 10, e0143970.	1.1	45
132	Rheumatoid Arthritis: An Evolutionary Force in Biologics. <i>Current Pharmaceutical Design</i> , 2015, 21, 2170-2178.	0.9	12
133	Association of a complement receptor 1 gene variant with baseline erythrocyte sedimentation rate levels in patients starting anti-TNF therapy in a UK rheumatoid arthritis cohort: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort. <i>Pharmacogenomics Journal</i> , 2014, 14, 171-175.	0.9	3
134	Impact of Psychological Factors on Subjective Disease Activity Assessments in Patients With Severe Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2014, 66, 861-868.	1.5	71
135	Seronegative rheumatoid arthritis: Pathogenetic and therapeutic aspects. <i>Best Practice and Research in Clinical Rheumatology</i> , 2014, 28, 651-659.	1.4	55
136	The Darwin Awards: sex differences in idiotic behaviour. <i>BMJ, The</i> , 2014, 349, g7094-g7094.	3.0	20
137	Rheumatoid arthritis: from palliation to remission in two decades. <i>Clinical Medicine</i> , 2014, 14, s50-s55.	0.8	7
138	Prospects for therapeutic tolerance in humans. <i>Current Opinion in Rheumatology</i> , 2014, 26, 219-227.	2.0	11
139	Emerging immunotherapies for rheumatoid arthritis. <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 822-837.	1.4	17
140	Investigation of interleukin-6-driven STAT3 signalling in circulating lymphocytes of patients with early rheumatoid arthritis as a route to biomarker discovery. <i>Lancet, The</i> , 2014, 383, S84.	6.3	1
141	Evidence of NLRP3-inflammasome activation in rheumatoid arthritis (RA); genetic variants within the NLRP3-inflammasome complex in relation to susceptibility to RA and response to anti-TNF treatment. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1202-1210.	0.5	166
142	Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 349-356.	0.5	308
143	A Negative Feedback Loop Mediated by STAT3 Limits Human Th17 Responses. <i>Journal of Immunology</i> , 2014, 193, 1142-1150.	0.4	37
144	Testing the role of vitamin D in response to antitumour necrosis factor $\hat{\pm}$ therapy in a UK cohort: a Mendelian randomisation approach. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 938-940.	0.5	6

#	ARTICLE	IF	CITATIONS
145	The 2013 BSR and BHPR guideline for the use of intravenous tocilizumab in the treatment of adult patients with rheumatoid arthritis. <i>Rheumatology</i> , 2014, 53, 1344-1346.	0.9	18
146	Effect of inadequate adherence on clinical outcomes: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort. <i>Lancet, The</i> , 2014, 383, S26.	6.3	0
147	Changes in serum creatinine in patients with active rheumatoid arthritis treated with tofacitinib: results from clinical trials. <i>Arthritis Research and Therapy</i> , 2014, 16, R158.	1.6	40
148	Tofacitinib in Combination With Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis. <i>Annals of Internal Medicine</i> , 2013, 159, 253.	2.0	381
149	Treg Cells in Rheumatoid Arthritis: An Update. <i>Current Rheumatology Reports</i> , 2013, 15, 352.	2.1	87
150	Effect of tocilizumab on haematological markers implicates interleukin-6 signalling in the anaemia of rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2013, 15, R204.	1.6	80
151	What can rheumatologists learn from translational cancer therapy?. <i>Arthritis Research and Therapy</i> , 2013, 15, 114.	1.6	8
152	The role of biosimilars in the treatment of rheumatic diseases. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 322-328.	0.5	166
153	Tolerogenic dendritic cell therapy for rheumatoid arthritis: where are we now?. <i>Clinical and Experimental Immunology</i> , 2013, 172, 148-157.	1.1	134
154	Predicting persistent inflammatory arthritis amongst early arthritis clinic patients in the UK: is musculoskeletal ultrasound required?. <i>Arthritis Research and Therapy</i> , 2013, 15, R118.	1.6	29
155	Genome-Wide Association Study and Gene Expression Analysis Identifies CD84 as a Predictor of Response to Etanercept Therapy in Rheumatoid Arthritis. <i>PLoS Genetics</i> , 2013, 9, e1003394.	1.5	146
156	Effect of baseline rheumatoid factor and anticitrullinated peptide antibody serotype on rituximab clinical response: a meta-analysis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 329-336.	0.5	158
157	Novel immunotherapies for rheumatoid arthritis. <i>Clinical Medicine</i> , 2013, 13, 391-394.	0.8	6
158	Safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of the monoclonal antibody ASK8007 blocking osteopontin in patients with rheumatoid arthritis: a randomised, placebo controlled, proof-of-concept study. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 180-185.	0.5	43
159	Immunity 12 years after alemtuzumab in RA: CD5+ B-cell depletion, thymus-dependent T-cell reconstitution and normal vaccine responses. <i>Rheumatology</i> , 2012, 51, 1397-1406.	0.9	18
160	Rheumatology Conference Highlights. <i>International Journal of Clinical Rheumatology</i> , 2012, 7, 33-35.	0.3	0
161	Correlation of C-reactive protein haplotypes with serum C-reactive protein level and response to anti-tumor necrosis factor therapy in UK rheumatoid arthritis patients: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort. <i>Arthritis Research and Therapy</i> , 2012, 14, R214.	1.6	18
162	Adrenal Steroidogenesis after B Lymphocyte Depletion Therapy in New-Onset Addison's Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, E1927-E1932.	1.8	33

#	ARTICLE	IF	CITATIONS
163	Disease activity and cognition in rheumatoid arthritis: an open label pilot study. <i>Arthritis Research and Therapy</i> , 2012, 14, R263.	1.6	20
164	Baseline serum MMP-3 levels in patients with Rheumatoid Arthritis are still independently predictive of radiographic progression in a longitudinal observational cohort at 8 years follow up. <i>Arthritis Research and Therapy</i> , 2012, 14, R30.	1.6	66
165	A CD4 T cell gene signature for early rheumatoid arthritis implicates interleukin 6-mediated STAT3 signalling, particularly in anti-citrullinated peptide antibody-negative disease. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1374-1381.	0.5	67
166	Frailty and the role of inflammation, immunosenescence and cellular ageing in the very old: Cross-sectional findings from the Newcastle 85+ Study. <i>Mechanisms of Ageing and Development</i> , 2012, 133, 456-466.	2.2	347
167	Confirmation of association of FCGR3B but not FCGR3A copy number with susceptibility to autoantibody positive rheumatoid arthritis. <i>Human Mutation</i> , 2012, 33, 741-749.	1.1	36
168	Replication of association of the <i>PTPRC</i> gene with response to anti-tumor necrosis factor therapy in a large UK cohort. <i>Arthritis and Rheumatism</i> , 2012, 64, 665-670.	6.7	65
169	FcγRIIIa Expression on Monocytes in Rheumatoid Arthritis: Role in Immune-Complex Stimulated TNF Production and Non-Response to Methotrexate Therapy. <i>PLoS ONE</i> , 2012, 7, e28918.	1.1	49
170	Efficacy of a single ultrasound-guided injection for the treatment of hip osteoarthritis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 110-116.	0.5	133
171	Biologic therapies in non-rheumatic diseases: lessons for rheumatologists?. <i>Nature Reviews Rheumatology</i> , 2011, 7, 507-516.	3.5	17
172	Integrated safety in tocilizumab clinical trials. <i>Arthritis Research and Therapy</i> , 2011, 13, R141.	1.6	278
173	Anti-TNF therapy. <i>Best Practice and Research in Clinical Rheumatology</i> , 2011, 25, 549-567.	1.4	113
174	Prevalence and diagnostic outcome relating to vitamin D deficiency in new patients presenting to an early arthritis clinic over 12 months. <i>Clinical Rheumatology</i> , 2011, 30, 1137-1138.	1.0	4
175	Genome-wide association study of genetic predictors of anti-tumor necrosis factor treatment efficacy in rheumatoid arthritis identifies associations with polymorphisms at seven loci. <i>Arthritis and Rheumatism</i> , 2011, 63, 645-653.	6.7	143
176	Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 909-920.	0.5	394
177	Genetic variants within the MAP kinase signalling network and anti-TNF treatment response in rheumatoid arthritis patients. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 98-103.	0.5	55
178	Serotyping for an extended anti-citrullinated peptide autoantibody panel does not add value to CCP2 testing for diagnosing RA in an early undifferentiated arthritis cohort. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 2056-2058.	0.5	9
179	Pathophysiology of rheumatoid arthritis. <i>Current Opinion in Rheumatology</i> , 2011, 23, 233-240.	2.0	151
180	The need for personalised medicine for rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 4-7.	0.5	88

#	ARTICLE	IF	CITATIONS
181	Epstein-Barr virus-driven lymphoproliferative disorder post-CAMPATH-1H (alemtuzumab) in refractory polymyositis. <i>Rheumatology</i> , 2011, 50, 810-812.	0.9	9
182	Polymorphisms spanning the TNFR2 and TACE genes do not contribute towards variable anti-TNF treatment response. <i>Pharmacogenetics and Genomics</i> , 2010, 20, 338-341.	0.7	12
183	Low-strength T-cell activation promotes Th17 responses. <i>Blood</i> , 2010, 116, 4829-4837.	0.6	108
184	Tumour necrosis factor alpha blockade impairs dendritic cell survival and function in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1200-1207.	0.5	57
185	Treating to re-establish tolerance in inflammatory arthritis – lessons from other diseases. <i>Best Practice and Research in Clinical Rheumatology</i> , 2010, 24, 497-511.	1.4	6
186	A randomized, double-blind, controlled study of ultrasound-guided corticosteroid injection into the joint of patients with inflammatory arthritis. <i>Arthritis and Rheumatism</i> , 2010, 62, 1862-1869.	6.7	175
187	Rheumatoid arthritis risk allele <i>PTPRC</i> is also associated with response to anti-tumor necrosis factor therapy. <i>Arthritis and Rheumatism</i> , 2010, 62, 1849-1861.	6.7	95
188	Therapeutic effect of tolerogenic dendritic cells in established collagen-induced arthritis is associated with a reduction in Th17 responses. <i>Arthritis and Rheumatism</i> , 2010, 62, 3656-3665.	6.7	129
189	Genome-wide association study of CNVs in 16,000 cases of eight common diseases and 3,000 shared controls. <i>Nature</i> , 2010, 464, 713-720.	13.7	737
190	The changing face of rheumatoid arthritis: sustained remission for all?. <i>Nature Reviews Immunology</i> , 2010, 10, 605-611.	10.6	74
191	Dissection of the FCGR3A association with RA: increased association in men and with autoantibody positive disease. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1054-1057.	0.5	55
192	Association between anti-tumour necrosis factor treatment response and genetic variants within the TLR and NF- κ B signalling pathways. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1315-1320.	0.5	74
193	Profound invariant natural killer T-cell deficiency in inflammatory arthritis. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1873-1879.	0.5	27
194	Genotype at the sIL-6R A358C polymorphism does not influence response to anti-TNF therapy in patients with rheumatoid arthritis. <i>Rheumatology</i> , 2010, 49, 43-47.	0.9	9
195	Investigation of rheumatoid arthritis susceptibility genes identifies association of AFF3 and CD226 variants with response to anti-tumour necrosis factor treatment. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1029-1035.	0.5	89
196	Translating cutting edge science into novel and effective therapies. <i>Current Opinion in Pharmacology</i> , 2010, 10, 300-301.	1.7	0
197	Generation and characterisation of therapeutic tolerogenic dendritic cells for rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 2042-2050.	0.5	186
198	Development of Dendritic Cell-Based Immunotherapy for Autoimmunity. <i>International Reviews of Immunology</i> , 2010, 29, 156-183.	1.5	150

#	ARTICLE	IF	CITATIONS
199	Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders (SERENE)). <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1629-1635.	0.5	296
200	Tolerogenic Dendritic Cells in Clinical Practice. <i>Open Arthritis Journal</i> , 2010, 3, 8-12.	0.0	4
201	LPS activation is required for migratory activity and antigen presentation by tolerogenic dendritic cells. <i>Journal of Leukocyte Biology</i> , 2009, 85, 243-250.	1.5	112
202	Atacicept, a novel B cell-targeting biological therapy for the treatment of rheumatoid arthritis. <i>Expert Opinion on Biological Therapy</i> , 2009, 9, 909-919.	1.4	40
203	Thymic function in juvenile idiopathic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2009, 68, 983-990.	0.5	20
204	Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or <i>PTPN22</i> susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2009, 68, 69-74.	0.5	240
205	Therapeutic agents for patients with rheumatoid arthritis and an inadequate response to tumour necrosis factor- α antagonists. <i>Expert Opinion on Biological Therapy</i> , 2009, 9, 1463-1475.	1.4	35
206	Current concepts in the pathogenesis of early rheumatoid arthritis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2009, 23, 37-48.	1.4	51
207	Animal models in infection and inflammation – chance and necessity. <i>European Journal of Immunology</i> , 2009, 39, 1991-1993.	1.6	12
208	Thymic function and immune senescence in juvenile idiopathic arthritis: Comment on the article by Prelog et al. <i>Arthritis and Rheumatism</i> , 2009, 60, 310-311.	6.7	0
209	Antibody engineering to develop new antirheumatic therapies. <i>Arthritis Research and Therapy</i> , 2009, 11, 225.	1.6	21
210	Will treatment of rheumatoid arthritis with an IL-6R inhibitor help facilitate the ‘‘age of remission’’?. <i>Expert Opinion on Investigational Drugs</i> , 2009, 18, 1687-1699.	1.9	7
211	Regulatory T cells and autoimmunity. <i>Current Opinion in Hematology</i> , 2009, 16, 274-279.	1.2	52
212	Investigation of genetic variants within candidate genes of the TNFRSF1B signalling pathway on the response to anti-TNF agents in a UK cohort of rheumatoid arthritis patients. <i>Pharmacogenetics and Genomics</i> , 2009, 19, 319-323.	0.7	35
213	Morbidity and mortality in rheumatoid arthritis patients with prolonged therapy-induced lymphopenia: Twelve-year outcomes. <i>Arthritis and Rheumatism</i> , 2008, 58, 370-375.	6.7	44
214	Determination of thymic function directly from peripheral blood: A validated modification to an established method. <i>Journal of Immunological Methods</i> , 2008, 339, 185-194.	0.6	49
215	A novel paradigm for dendritic cells as effectors of cartilage destruction. <i>Rheumatology</i> , 2008, 48, 502-507.	0.9	18
216	Association of the tumour necrosis factor-308 variant with differential response to anti-TNF agents in the treatment of rheumatoid arthritis. <i>Human Molecular Genetics</i> , 2008, 17, 3532-3538.	1.4	111

#	ARTICLE	IF	CITATIONS
217	Differential regulation of naïve and memory CD4+ T cells by alternatively activated dendritic cells. <i>Journal of Leukocyte Biology</i> , 2008, 84, 124-133.	1.5	113
218	Abnormal T cell differentiation persists in patients with rheumatoid arthritis in clinical remission and predicts relapse. <i>Annals of the Rheumatic Diseases</i> , 2008, 67, 750-757.	0.5	35
219	A pilot study of combination anti-cytokine and anti-lymphocyte biological therapy in rheumatoid arthritis. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2008, 101, 299-306.	0.2	12
220	From mice to men: the challenges of developing tolerance-inducing biological drugs for the clinic. , 2008, , 169-185.		2
221	Alemtuzumab (Campath-1H) for treatment of refractory polymyositis. <i>Journal of Rheumatology</i> , 2008, 35, 2080-2.	1.0	22
222	T cell responses to a non-glycosylated epitope predominate in type II collagen-immunised HLA-DRB1*0101 transgenic mice. <i>Annals of the Rheumatic Diseases</i> , 2007, 66, 599-604.	0.5	12
223	T cell immunomodulation—the Holy Grail of therapeutic tolerance. <i>Current Opinion in Pharmacology</i> , 2007, 7, 418-425.	1.7	24
224	Adult Human Fibroblasts Are Potent Immunoregulatory Cells and Functionally Equivalent to Mesenchymal Stem Cells. <i>Journal of Immunology</i> , 2007, 179, 1595-1604.	0.4	319
225	Biologic therapies in rheumatology: lessons learned, future directions. <i>Nature Reviews Drug Discovery</i> , 2007, 6, 75-92.	21.5	178
226	Differential Display Reverse Transcription-Polymerase Chain Reaction to Identify Novel Biomolecules in Arthritis Research. <i>Methods in Molecular Medicine</i> , 2007, 136, 329-347.	0.8	0
227	Inhibition of macropinocytosis blocks antigen presentation of type II collagen in vitro and in vivo in HLA-DR1 transgenic mice. <i>Arthritis Research and Therapy</i> , 2006, 8, R93.	1.6	40
228	Association of FCGR2A and FCGR2A-FCGR3A haplotypes with susceptibility to giant cell arteritis. <i>Arthritis Research and Therapy</i> , 2006, 8, R109.	1.6	47
229	Analysis of Fcγ receptor haplotypes in rheumatoid arthritis: FCGR3A remains a major susceptibility gene at this locus, with an additional contribution from FCGR3B. <i>Arthritis Research and Therapy</i> , 2006, 8, R5.	1.6	39
230	The impact of glycosylation on HLA-DR1-restricted T cell recognition of type II collagen in a mouse model. <i>Arthritis and Rheumatism</i> , 2006, 54, 482-491.	6.7	25
231	Outcome of intensive immunosuppression and autologous stem cell transplantation in patients with severe rheumatoid arthritis is associated with the composition of synovial T cell infiltration. <i>Annals of the Rheumatic Diseases</i> , 2005, 64, 1397-1405.	0.5	36
232	A Non-Glycosaminoglycan-Binding Variant of CC Chemokine Ligand 7 (Monocyte Chemoattractant) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	0.4	66
233	CD4+CD25+ T-regulatory cells are decreased in patients with autoimmune polyendocrinopathy candidiasis ectodermal dystrophy. <i>Journal of Allergy and Clinical Immunology</i> , 2005, 116, 1158-1159.	1.5	65
234	Interleukin-7 deficiency in rheumatoid arthritis: consequences for therapy-induced lymphopenia. <i>Arthritis Research</i> , 2005, 7, R80.	2.0	75

#	ARTICLE	IF	CITATIONS
235	Neutralizing Tumor Necrosis Factor Activity Leads to Remission in Patients With Refractory Noninfectious Posterior Uveitis. <i>JAMA Ophthalmology</i> , 2004, 122, 845.	2.6	64
236	Analysis of the insertion/deletion related polymorphism within T cell antigen receptor \hat{A} variable genes in primary Sjogren's syndrome. <i>Annals of the Rheumatic Diseases</i> , 2004, 64, 468-470.	0.5	7
237	Anti-TNF $\hat{\pm}$ Therapy Modulates the Phenotype of Peripheral Blood CD4+T Cells in Patients with Posterior Segment Intraocular Inflammation. , 2004, 45, 170.		59
238	Fc γ receptors are critical modulators of inflammation within the synovium: Comment on the article by Blom et al. <i>Arthritis and Rheumatism</i> , 2004, 50, 1352-1353.	6.7	0
239	Immune reconstitution. <i>Best Practice and Research in Clinical Haematology</i> , 2004, 17, 345-358.	0.7	13
240	Elucidation of the relationship between synovitis and bone damage: A randomized magnetic resonance imaging study of individual joints in patients with early rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2003, 48, 64-71.	6.7	440
241	Real-time PCR based on SYBR-Green I fluorescence: an alternative to the TaqMan assay for a relative quantification of gene rearrangements, gene amplifications and micro gene deletions. <i>BMC Biotechnology</i> , 2003, 3, 18.	1.7	281
242	Long-term immunologic effects of alemtuzumab: immune reconstitution and immune function after alemtuzumab therapy for autoimmune disease. <i>Transplantation Reviews</i> , 2003, 17, S12-S15.	1.2	3
243	Overexpression of transcripts containing LINE-1 in the synovia of patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2003, 62, 663-666.	0.5	23
244	Promoter switch: a novel mechanism causing biallelic PEG1/MEST expression in invasive breast cancer. <i>Human Molecular Genetics</i> , 2002, 11, 1449-1453.	1.4	44
245	Dysregulated lymphocyte proliferation and differentiation in patients with rheumatoid arthritis. <i>Blood</i> , 2002, 100, 4550-4556.	0.6	152
246	High-dose cyclophosphamide with stem cell rescue for severe rheumatoid arthritis: Short-term efficacy correlates with reduction of macroscopic and histologic synovitis. <i>Arthritis and Rheumatism</i> , 2002, 46, 837-839.	6.7	44
247	Unique TCR $\hat{\gamma}$ -subunit variable gene haplotypes in Africans. <i>Immunogenetics</i> , 2002, 53, 884-893.	1.2	4
248	Human CD4+CD25+ cells: a naturally occurring population of regulatory T cells. <i>Blood</i> , 2001, 98, 2736-2744.	0.6	551
249	Morbidity and mortality in rheumatoid arthritis patients with prolonged and profound therapy-induced lymphopenia. <i>Arthritis and Rheumatism</i> , 2001, 44, 1998-2008.	6.7	75
250	Application of differential display to immunological research. <i>Journal of Immunological Methods</i> , 2001, 250, 29-43.	0.6	23
251	Detection of Mycobacterium tuberculosis Group Organisms in Human and Mouse Joint Tissue by Reverse Transcriptase PCR: Prevalence in Diseased Synovial Tissue Suggests Lack of Specific Association with Rheumatoid Arthritis. <i>Infection and Immunity</i> , 2001, 69, 1821-1831.	1.0	20
252	Does the shared epitope genotype influence either the susceptibility to or the phenotype of corneal melting?. <i>Eye</i> , 2001, 15, 492-496.	1.1	5

#	ARTICLE	IF	CITATIONS
253	Rheumatoid arthritis synovial T cells regulate transcription of several genes associated with antigen-induced energy. <i>Journal of Clinical Investigation</i> , 2001, 107, 519-528.	3.9	36
254	Fcγ ₃ receptor type IIIA is associated with rheumatoid arthritis in two distinct ethnic groups. <i>Arthritis and Rheumatism</i> , 2000, 43, 2328-2334.	6.7	103
255	The value of sonography in the detection of bone erosions in patients with rheumatoid arthritis: A comparison with conventional radiography. <i>Arthritis and Rheumatism</i> , 2000, 43, 2762-2770.	6.7	611
256	Local bioactive tumour necrosis factor (TNF) in corneal allotransplantation. <i>Clinical and Experimental Immunology</i> , 2000, 122, 109-116.	1.1	39
257	Campath-1H therapy in refractory ocular inflammatory disease. <i>British Journal of Ophthalmology</i> , 2000, 84, 107-109.	2.1	105
258	No strong association between alleles of tumour necrosis factor alpha and interleukin-1 receptor antagonist and corneal melting associated with systemic vasculitis. <i>British Journal of Ophthalmology</i> , 2000, 84, 395-398.	2.1	1
259	Incidence of corneal melting in association with systemic disease in the Yorkshire Region, 1995-7. <i>British Journal of Ophthalmology</i> , 1999, 83, 941-943.	2.1	61
260	Activated polyamidoamine dendrimers, a non-viral vector for gene transfer to the corneal endothelium. <i>Gene Therapy</i> , 1999, 6, 939-943.	2.3	137
261	Neutralizing TNF-alpha Activity Modulates T-cell Phenotype and Function in Experimental Autoimmune Uveoretinitis. <i>Journal of Autoimmunity</i> , 1998, 11, 255-264.	3.0	103
262	Extended clomiphene citrate (CC) and prednisone for the treatment of chronic anovulation resistant to CC alone. <i>Fertility and Sterility</i> , 1997, 67, 641-643.	0.5	34
263	Cumulative pregnancy analysis of one-tube versus two-tube tubal anastomosis. <i>Fertility and Sterility</i> , 1997, 68, 217-219.	0.5	8
264	A phase 1 study to address the safety and efficacy of granulocyte colony-stimulating factor for the mobilization of hematopoietic progenitor cells in active rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 1997, 40, 1838-1842.	6.7	25
265	Life-threatening neutropenia following methotrexate treatment of ectopic pregnancy: A report of two cases. <i>Obstetrics and Gynecology</i> , 1996, 88, 694-696.	1.2	72
266	Endometrial thickness is a valid monitoring parameter in cycles of ovulation induction with menotropins alone. <i>Fertility and Sterility</i> , 1996, 65, 262-266.	0.5	85
267	A therapeutic human IgG4 monoclonal antibody that depletes target cells in humans. <i>Clinical and Experimental Immunology</i> , 1996, 106, 427-433.	1.1	89
268	Short term immunosuppressive therapy and long-term immunoregulation: promises and problems.. <i>British Journal of Ophthalmology</i> , 1996, 80, 1035-1036.	2.1	7
269	Transient increase in symptoms associated with cytokine release in patients with multiple sclerosis. <i>Brain</i> , 1996, 119, 225-237.	3.7	249
270	Mechanism of first-dose cytokine-release syndrome by CAMPATH 1-H: involvement of CD16 (Fcγ ₃) and CD11a/CD18 (LFA-1) on NK cells.. <i>Journal of Clinical Investigation</i> , 1996, 98, 2819-2826.	3.9	227

#	ARTICLE	IF	CITATIONS
271	Maternal Acute Fatty Liver of Pregnancy Associated with Fetal Trifunctional Protein Deficiency: Molecular Characterization of a Novel Maternal Mutant Allele. <i>Pediatric Research</i> , 1996, 40, 393-398.	1.1	73
272	Monoclonal antibody therapy of chronic intraocular inflammation using Campath-1H.. <i>British Journal of Ophthalmology</i> , 1995, 79, 1054-1055.	2.1	42
273	Prevention of immune-mediated corneal graft destruction with the anti-lymphocyte monoclonal antibody, CAMPATH-1H. <i>Eye</i> , 1995, 9, 564-569.	1.1	51
274	Long-term remission of intractable systemic vasculitis with monoclonal antibody therapy. <i>Lancet</i> , The, 1993, 341, 1620-1622.	6.3	204
275	Immunotherapy of rheumatoid arthritis.. <i>Annals of the Rheumatic Diseases</i> , 1992, 51, 577-579.	0.5	11
276	Humanised monoclonal antibody therapy for rheumatoid arthritis. <i>Lancet</i> , The, 1992, 340, 748-752.	6.3	309
277	Therapeutic immunosuppression of T cells. <i>Current Opinion in Biotechnology</i> , 1992, 3, 668-674.	3.3	1
278	High Frequency of Anti-Drug Antibodies and Correlation of Low Random Drug Levels with Lack of Efficacy in Certolizumab Pegol-Treated Patients with Rheumatoid Arthritis. <i>Rheumatology</i> , 0, , .	0.9	0